$27.98
+1.71%Price chart
Jul 14Jul 17Jul 22Jul 27Jul 30Aug 4Aug 7Aug 12
Key dataAug 12, 2026
Open$28.33
From 52W high−25.62%
Volume375197.00
Market cap$1.84B
P/E (TTM)3.4x
P/S (TTM)1.6x
Div yield—
Key dataAug 12, 2026
Open
$28.33
From 52W high
−25.62%
Volume
375197.00
Market cap
$1.84B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.5x
P/E (TTM)
3.4x
RSI (14)
49.4
MomentumView details →
1D Return
+1.71%
YTD Return
−14.59%
SummaryUpdated Mar 1, 2026
Galapagos NV (NASDAQ:GLPG) is a Belgian integrated biopharmaceutical company founded in 1999 and headquartered in Mechelen, Belgium. The company went public in 2012 and has evolved from a drug discovery platform into a focused biotechnology company developing innovative therapies for high unmet medical needs. Originally operating across multiple therapeutic areas, Galapagos has undergone significant strategic transformation in recent years, narrowing its focus to oncology and immunology while divesting non-core assets. The company is currently planning a major corporate restructuring that will separate it into two distinct entities by mid-2025.
Similar companies
Latest newsMore news →
Lakefront Biotherapeutics completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics.5d agoLakefront Biotherapeutics repurchased 126,322 of its own shares for €3,317,407.94 under its repurchase program.6d agoLakefront Biotherapeutics repurchased 117,437 of its shares between September 28 and October 2, 2026, through a discretionary mandate to an independent financial intermediary.13d ago